Cholangiocarcinoma is cancer that arises from the cells lining the bile ducts, the network of thin tubes that carry bile from the liver to the small intestine. It accounts for a meaningful share of primary liver cancers worldwide, with roughly 217,000 new cases of gallbladder and biliary tract cancers reported globally in 2021.1European Journal of Gastroenterology & Hepatology. Global trends and disparities in gallbladder and biliary tract cancers: insights from the global burden of disease study 2021 It is notoriously difficult to diagnose early, tends to resist standard chemotherapy, and for most patients still carries a poor prognosis. Yet the landscape has shifted in the past few years, with molecular profiling and immunotherapy opening treatment options that did not exist a decade ago.
Where It Starts and Why That Matters
Bile ducts branch through the liver and converge into a single common duct before reaching the intestine, and a tumor can form anywhere along that path. Based on location, cholangiocarcinoma falls into three types: intrahepatic (inside the liver), perihilar (at the junction where the main ducts exit the liver), and distal (the portion closer to the intestine).2PubMed. Pathologic classification of cholangiocarcinoma: New concepts The distinction is not academic. Each subtype behaves differently, looks different under a microscope, responds differently to treatment, and tends to carry different genetic mutations.
Perihilar tumors are the most common form and sit in a surgically difficult spot where the right and left hepatic ducts merge. Distal tumors resemble pancreatic cancer in many respects and are often managed with similar surgical approaches. Intrahepatic cholangiocarcinoma, which arises deeper within the liver, has itself been further divided into large-duct and small-duct subtypes, each thought to originate from different stem-cell populations in the biliary tree.3PubMed. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type The large-duct variety tends to resemble perihilar cancer in its biology and outlook, while the small-duct type is more associated with chronic liver disease and may carry a somewhat different prognosis.
Known Risk Factors
Most people diagnosed with cholangiocarcinoma have no identifiable risk factor at all, which is part of what makes it so frustrating. Still, several conditions clearly increase the odds, and they vary dramatically by geography.
Liver Flukes
In parts of Southeast Asia, particularly Thailand, Laos, Cambodia, and Vietnam, infection with the parasitic liver flukes Opisthorchis viverrini and Clonorchis sinensis is the dominant driver. These flatworms take up residence in the bile ducts after a person eats raw or underfermented freshwater fish. The parasites secrete growth factors and enzymes, physically graze on the duct lining, and trigger cycles of chronic wounding and repair that, over years, push cells toward malignant transformation.4PubMed Central. Mechanistic insights into liver-fluke-induced bile-duct cancer The result is a strikingly high rate of cholangiocarcinoma in endemic regions. The carcinogenesis pathway involves mechanical damage, immune reactions to the fluke’s secretions, changes in the biliary microbiome, and the cumulative effects of repeated antiparasitic treatment cycles.5PubMed Central. Liver Fluke-Associated Biliary Tract Cancer
Primary Sclerosing Cholangitis
In Western countries, primary sclerosing cholangitis (PSC) is the best-recognized predisposing condition. PSC causes progressive scarring and inflammation of the bile ducts, and nearly half of deaths among PSC patients are attributed to cancer, with cholangiocarcinoma the most common.6PubMed Central. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies The chronic inflammation appears to generate DNA-damaging molecules that promote mutations in known cancer-driver genes. Recent work examining bile duct tissue from PSC patients found clonal expansion of cells carrying mutations in genes like ARID1A and KRAS, suggesting that cancer-promoting changes may be underway well before a visible tumor forms.7Cancer Research. Abstract 3887: Clonal expansion in the bile duct associated with primary sclerosing cholangitis
Metabolic and Lifestyle Factors
Fatty liver disease has emerged as an increasingly recognized risk factor. A meta-analysis found that non-alcoholic fatty liver disease roughly doubled the odds of cholangiocarcinoma overall, with similar increases for both the intrahepatic and extrahepatic subtypes.8PubMed Central. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis High body mass index was identified as the leading modifiable risk factor in the 2021 Global Burden of Disease analysis, contributing to about 12% of disability-adjusted life years from biliary tract cancers.9European Journal of Gastroenterology & Hepatology. Global trends and disparities in gallbladder and biliary tract cancers: insights from the global burden of disease study 2021 Viral hepatitis (B and C), cirrhosis of any cause, hepaticolithiasis (stones within the bile ducts inside the liver), biliary cystic diseases, alcohol abuse, and tobacco use round out the list of established or probable risk factors.10PubMed Central. Epidemiology and risk factors: intrahepatic cholangiocarcinoma
Occupational Chemical Exposure
A striking cluster of cholangiocarcinoma cases among Japanese printing workers in the early 2010s drew attention to an occupational hazard. Workers exposed to the industrial solvents 1,2-dichloropropane and dichloromethane for years developed bile duct cancer at extraordinary rates. One analysis calculated a standardized mortality ratio of 2,900, meaning these workers died of cholangiocarcinoma at roughly 29 times the expected rate.11Occupational and Environmental Medicine. Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane Follow-up studies confirmed elevated chemical exposure levels at the affected workplaces and supported a causal link, particularly for dichloromethane.12PubMed. Chemical exposure levels in printing workers with cholangiocarcinoma (second report) The episode remains one of the clearest examples of an occupational cause for this cancer.
Why It Is So Hard to Catch Early
Cholangiocarcinoma is one of the cancers where a delayed diagnosis is the rule rather than the exception. The tumors tend to grow lengthwise along the bile duct wall rather than forming an obvious mass, which means standard imaging techniques often miss them or cannot distinguish them from a benign narrowing.13PubMed Central. Diagnostic approaches for cholangiocarcinoma Ultrasound, CT, and MRI each have limited sensitivity for this pattern of growth.
When a suspicious stricture is found, doctors typically try to get tissue through endoscopic or percutaneous procedures. Even so, brushing cells from the inside of the duct or taking a small biopsy confirms cancer in only about half of patients, a frustratingly low yield that means some people must undergo repeat procedures or go to surgery without a definitive tissue diagnosis.14PubMed Central. Diagnostic approaches for cholangiocarcinoma
The blood marker CA19-9 is widely used as an adjunct, but it is far from perfect. A meta-analysis found a pooled sensitivity of about 72% and specificity of about 84%, which translates to a test that catches most cases but still misses a meaningful fraction and sometimes lights up for other conditions entirely.15PubMed Central. Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis People who lack a certain blood-group enzyme (the Lewis antigen, roughly 5 to 10% of the population) cannot produce CA19-9 at all, rendering the test useless for them. Researchers have explored combining CA19-9 with tumor volume measurements to improve prognostic accuracy, but that approach is still being validated.16PubMed Central. Developing a Prognostic Model for Intrahepatic Cholangiocarcinoma Patients With Elevated Preoperative Carbohydrate Antigen 19-9 Levels: Volume-Adjusted CA19-9 (VACA) as a Novel Biomarker
Symptoms That Bring People to the Doctor
What a person feels depends heavily on where the tumor sits. Perihilar and distal cholangiocarcinomas block the flow of bile relatively early, producing jaundice (yellowing of the skin and eyes), dark urine, pale stools, and itching. These symptoms tend to prompt medical evaluation, though by the time bile flow is blocked, the cancer may already be locally advanced. Intrahepatic tumors, by contrast, can grow quietly for a long time because they do not obstruct the main bile ducts until they are large. Patients may notice only vague abdominal discomfort, fatigue, or unintended weight loss, symptoms easy to dismiss or attribute to something else. That is a major reason intrahepatic cholangiocarcinoma is so often diagnosed at an advanced stage.
Surgery and Transplantation
Complete surgical removal remains the only realistic chance for long-term survival, but only a minority of patients have disease contained enough to attempt it. The specifics of the operation depend on where the tumor is: intrahepatic disease requires removal of part of the liver, perihilar disease often demands a major liver resection combined with bile duct reconstruction, and distal disease is typically treated with a Whipple procedure.
Getting a clear surgical margin, meaning no cancer cells visible at the cut edge, has a strong influence on outcome. One study of extrahepatic bile duct cancer found that patients with negative margins had a median survival of about 45 months and a 10-year survival rate around 40%.17PubMed. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma In patients with positive margins, the picture split sharply: those whose margin showed only carcinoma in situ (precancerous change) still fared relatively well, while those with invasive cancer at the margin had a median survival of just 21 months and no five-year survivors at all.18PubMed. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma For perihilar tumors, when a frozen-section biopsy during surgery reveals a positive margin, going back and resecting more tissue to achieve a clear margin can match the survival of patients whose margins were clean on the first cut, with a median survival of roughly 30 months in both groups.19Annals of Surgery. Additional Resection of an Intraoperative Margin-Positive Proximal Bile Duct Improves Survival in Patients With Hilar Cholangiocarcinoma
For a carefully selected subset of patients with perihilar cholangiocarcinoma that cannot be removed conventionally, liver transplantation following a rigorous neoadjuvant protocol of chemotherapy and radiation has produced impressive results. A meta-analysis found that among patients who completed neoadjuvant chemoradiation before transplant, one-year survival exceeded 80% and five-year survival was roughly 65%, with a three-year recurrence rate of about 24%.20Annals of Surgery. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma Without neoadjuvant treatment, recurrence was far higher, over 50% at three years. This transplant approach, pioneered under the Mayo Clinic protocol, demands strict patient selection and remains available at only a limited number of centers.21PubMed Central. Liver transplantation in the management of perihilar cholangiocarcinoma
Chemotherapy and Immunotherapy
For patients with advanced or metastatic disease who are not surgical candidates, systemic therapy is the mainstay. The backbone has long been gemcitabine combined with cisplatin. The meaningful development in recent years has been the addition of immunotherapy to that backbone.
A large phase 3 trial (KEYNOTE-966) found that adding the checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin improved median overall survival from about 11 months to nearly 13 months, a modest but statistically significant gain.22The Lancet. Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial A phase 2 study adding a different checkpoint inhibitor, durvalumab, with or without tremelimumab, showed a high objective response rate, with about two-thirds of patients experiencing tumor shrinkage.23The Lancet Gastroenterology & Hepatology. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in untreated advanced biliary tract cancer: a phase 2 study Gemcitabine, cisplatin, and durvalumab is now widely regarded as a standard first-line regimen.24PubMed Central. Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab
It is worth noting that “biliary tract cancer” in many of these trials includes gallbladder cancer and ampullary cancer alongside cholangiocarcinoma. The trials are grouped this way because these cancers are rare enough that enrolling sufficient patients for each separately would be extremely slow. That means the headline survival numbers reflect a mixed population, and an individual cholangiocarcinoma patient’s response may differ from the trial average.
Targeted Therapy and Molecular Profiling
One of the most consequential shifts in cholangiocarcinoma treatment has been the recognition that these tumors carry a high rate of actionable genetic alterations, genetic changes that specific drugs can exploit. This is especially true for the intrahepatic subtype.
Roughly 10 to 15% of intrahepatic cholangiocarcinomas harbor fusions or rearrangements in the FGFR2 gene, which drives tumor growth through abnormal signaling.25British Journal of Cancer. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing Several FGFR-targeting drugs have now entered clinical practice. Futibatinib, for example, received approval for FGFR2-rearranged intrahepatic cholangiocarcinoma that has progressed after prior treatment.26PubMed. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma Other FGFR inhibitors, including pemigatinib and infigratinib, have also shown activity. Mutations in IDH1, another enzyme involved in cell metabolism, are found in a comparable fraction of intrahepatic tumors, and the IDH1 inhibitor ivosidenib has demonstrated a survival benefit in that subset.27PubMed Central. Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1
Beyond FGFR2 and IDH1, researchers are pursuing several other targets. The BRAF V600E mutation, found in a small percentage of biliary tract cancers, responds to the combination of dabrafenib and trametinib, which produced tumor shrinkage in about half of treated patients in a phase 2 trial.28PubMed Central. Targeted therapies in advanced biliary tract cancers—a narrative review HER2 amplification, present in up to 18% of extrahepatic cholangiocarcinomas, is another area of active investigation.29PubMed Central. Targeted therapies in advanced biliary tract cancers—a narrative review The cumulative message is that molecular profiling of the tumor, typically through next-generation sequencing, is now essential rather than optional. A patient whose tumor turns out to carry an FGFR2 fusion or an IDH1 mutation has a treatment pathway that simply did not exist a few years ago.
Radioembolization for Unresectable Intrahepatic Disease
When intrahepatic cholangiocarcinoma cannot be surgically removed but remains confined to the liver, a procedure called radioembolization offers a locoregional alternative. Tiny radioactive beads (typically yttrium-90) are delivered through the hepatic artery directly into the blood vessels feeding the tumor, delivering a high local radiation dose while largely sparing the surrounding liver. Intrahepatic cholangiocarcinoma appears to be relatively radiosensitive, and multiple studies have confirmed that the procedure is safe and produces meaningful anti-tumor responses.30PubMed Central. Yttrium-90 Radioembolization for Intrahepatic Cholangiocarcinoma: Safety, Response, and Survival Analysis A growing body of evidence supports a survival benefit, and the side-effect profile is generally favorable compared with systemic therapy.31PubMed Central. Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies In some cases, radioembolization can shrink a tumor enough to make a previously inoperable patient eligible for surgery, although this remains uncommon.
Relieving Bile Duct Blockages
For many patients whose tumors cannot be cured, one of the most impactful interventions is simply restoring the flow of bile. A blocked bile duct causes jaundice, relentless itching, and liver dysfunction, and relieving the obstruction can dramatically improve quality of life even when the underlying cancer cannot be eliminated.
Two main approaches exist: endoscopic biliary drainage, where a stent is placed through the mouth via endoscopy, and percutaneous transhepatic drainage, where a catheter is inserted through the skin into the liver. For distal obstructions, endoscopic stenting is generally the first choice and succeeds in more than 80% of cases.32PubMed Central. Endoscopic stent placement in the palliation of malignant biliary obstruction For hilar obstructions, the choice is more nuanced. Meta-analyses comparing the two routes have found similar overall complication rates and 30-day mortality, though after accounting for outlier studies, the percutaneous approach may have a higher success rate for restoring bile flow and a lower risk of post-procedure infection.33PubMed. Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis34PubMed Central. Percutaneous transhepatic and endoscopic biliary drainage for malignant biliary tract obstruction: a meta-analysis In practice, the decision often depends on institutional expertise and the specific anatomy of the blockage.
The Dense Tissue Problem
One reason cholangiocarcinoma resists treatment so stubbornly is a feature visible under the microscope: these tumors are surrounded and infiltrated by dense, fibrous connective tissue called desmoplastic stroma. In many solid tumors, the cancer cells themselves are the main target. In cholangiocarcinoma, the stroma can make up a larger proportion of the tumor mass than the actual malignant cells, forming a kind of protective shell. This dense tissue limits how much drug can physically reach the cancer cells and simultaneously sends growth signals that support tumor survival.35Trends in Cancer. The Tumor Microenvironment of Cholangiocarcinoma Strategies to disrupt the stroma are an active area of preclinical research, but no stroma-targeting drug has yet made it into routine clinical practice for this cancer.
Liquid Biopsy and What Comes Next
Getting tissue from a bile duct tumor is difficult, invasive, and often inconclusive. That reality has driven strong interest in liquid biopsy, particularly the detection of circulating tumor DNA (ctDNA) in a simple blood draw. Tumor cells shed fragments of their DNA into the bloodstream, and modern sequencing techniques can pick up cancer-specific mutations, including clinically actionable ones like FGFR2 fusions and IDH1 mutations, from a blood sample.36PubMed Central. Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives
The potential applications extend well beyond initial diagnosis. Serial blood draws can track whether a tumor is responding to treatment, detect early signs of recurrence, and identify new resistance mutations as they emerge. Two studies have already used liquid biopsy to uncover genetic mechanisms behind acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive tumors, something that would have required repeated invasive biopsies in the past.37PubMed Central. Cholangiocarcinoma: The era of liquid biopsy Liquid biopsy is not yet standard of care for cholangiocarcinoma, but it is edging closer, and for patients who cannot safely undergo tissue biopsy, it already offers a practical alternative for molecular profiling.
The Gut-Liver Axis
A newer line of research links cholangiocarcinoma to disruptions in the gut-liver axis, the biological dialogue between the intestinal microbiome, bile acid metabolism, and the liver’s immune environment. Patients with cholangiocarcinoma show significant shifts in the microbial populations of both the gut and the biliary tract, and these changes correlate with tumor stage, vascular invasion, and survival.38PubMed Central. Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions At the molecular level, the accumulation of certain primary bile acids appears to promote tumor invasiveness and help create an immune environment that shields the cancer from the body’s defenses.39Journal of Nutritional Oncology. Interplay among microbiota, bile acids, and tumor immunity in cholangiocarcinoma: The gut-biliary-liver axis The concept of a gut-biliary-liver axis is still in its early stages for cholangiocarcinoma, and no microbiome-based therapy is ready for the clinic. But it adds an intriguing dimension: the same bile acids these tumors arise alongside may actively participate in their growth and immune evasion.